<SEC-DOCUMENT>0001628280-19-014376.txt : 20191121
<SEC-HEADER>0001628280-19-014376.hdr.sgml : 20191121
<ACCEPTANCE-DATETIME>20191121082601
ACCESSION NUMBER:		0001628280-19-014376
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191119
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191121
DATE AS OF CHANGE:		20191121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		191235770

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xgn8-kxinnovatusloanam.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:54pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-top:4pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Washington, D.C. 20549 </font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">FORM 8-K </font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">CURRENT REPORT </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Pursuant to Section 13 or 15(d) </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">of the Securities Exchange Act of 1934 </font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Date of report (Date of earliest event reported)&#58; November 19, 2019 </font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:24pt;font-weight:700;line-height:120%;">EXAGEN INC. </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter) </font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.071429%;"><tr><td style="width:1.0%;"></td><td style="width:31.986928%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.107190%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:29.699346%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.107190%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:29.699346%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">001-39049</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20-0434866</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">(State or other jurisdiction</font></div><div style="text-align:center;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">of incorporation or organization)</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">(Commission</font></div><div style="text-align:center;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">File Number)</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">(I.R.S. Employer</font></div><div style="text-align:center;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">Identification No.)</font></div></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">1261 Liberty Way, Suite C </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Vista, CA 92081 </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">(Address of principal executive offices) (Zip Code) </font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(760) 560-1501 </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s telephone number, include area code) </font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">N&#47;A </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">(Former Name or Former Address, if Changed Since Last Report) </font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58; </font></div><div style="margin-top:3pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:0.1%;"></td><td style="width:1.125000%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.100000%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:85.797619%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.880952%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</font></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act&#58; </font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:30.886905%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.990476%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.589286%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.990476%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.142857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">Trading</font></div><div style="text-align:center;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">Symbol(s)</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">Name of each exchange</font></div><div style="text-align:center;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">on which registered</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock, par value $0.001 per share</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XGN</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">The Nasdaq Global Market</font></td></tr></table></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">Emerging growth company </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#9746; </font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> &#9744; </font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Item 1.01 Entry into a Material Definitive Agreement. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:115%;"> </font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Effective November 19, 2019, Exagen Inc. (the &#8220;Company&#8221;), entered into the First Amendment to Loan and Security Agreement with Innovatus Life Sciences Lending I, LP and the other lenders party thereto (the &#8220;Loan Amendment&#8221;), which amended the Company&#8217;s term loan agreement, dated as of September 7, 2017 (the &#8220;Original Loan Agreement&#8221;).</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Loan Amendment amends the Original Loan Agreement by, among other things, (i) decreasing the interest rate on all borrowings to 8.5%, of which 2.0% is paid in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until December 2022&#59; after which interest accrues at an annual rate of 8.5%&#59; (ii) extending the interest-only period to December 2022 and the maturity date to November 19, 2024&#59; (iii) revising the prepayment terms to (x) restrict prepayments for the initial year following the date of the Loan Amendment and (y) setting the prepayment premium at 3% of the principal amount of any term loans prepaid prior to November 19, 2020, with such prepayment premium decreasing by 1% during each subsequent twelve-month period after November 19, 2020&#59; and (iv) replacing the interest-only milestones with a financial covenant requiring that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, and commencing with the quarter ending December 31, 2019, subject to exceptions based on achievement of performance milestones and the ability to cure any default thereof with the issuance of equity securities or subordinated indebtedness. </font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The foregoing is a summary description of certain terms contained in the Loan Amendment and does not purport to be complete, and it is qualified in its entirety by reference to&#58; (i) the copy of the Original Loan Agreement, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as Exhibit 10.32 to the Company's Registration Statement on Form S-1 on August 23, 2019, (ii) the terms and conditions of the Loan Amendment, which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2019.</font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. </font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The information set forth above in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03.</font></div><div style="text-align:justify;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item 8.01.    Other Events. </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Press Release</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On November 21, 2019, the Company issued a press release announcing the entry into the Loan Amendment. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item 9.01. Financial Statements and Exhibits. </font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(d) Exhibits </font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:6.482143%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.315476%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:85.202381%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit No.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</font></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="6" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">99.1</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="xgnpr-innovatusloaname.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;">Press Release dated November 21, 2019</a></font></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="6" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div><font><br></font></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">SIGNATURES </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.220238%;"><tr><td style="width:1.0%;"></td><td style="width:42.208809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.105057%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.752039%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.105057%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.078303%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.105057%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:42.045677%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">EXAGEN INC.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="6" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; November 21, 2019</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>xgnpr-innovatusloaname.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:8pt;"><img alt="image01.jpg" src="image01.jpg" style="height:62px;width:171px;"></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:12pt;font-weight:700;line-height:120%;">Exagen Inc. Announces $26.2 Million Debt Refinancing</font></div><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">November 21, 2019</font></div><div><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">SAN DIEGO, CA &#8211; Exagen Inc. (Nasdaq&#58; XGN),&#160;an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innovatus Capital Partners, LLC (&#8220;Innovatus&#8221;).  The amended agreement provides a $26.2 million, 5-year term loan at 8.5% interest, of which 2.0% is paid in-kind in the form of additional term loans.  Additional information regarding the amendment is available in the company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 21, 2019.</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">&#8220;This refinancing is a continuation of Innovatus Capital Partners&#8217; investment in Exagen&#8217;s future.  This agreement, following our recent IPO, further strengthens our financial position and will assist us in executing on our strategic vision to &#8216;Own the Rheumatology Hilltop,&#8217;&#8221; said Ron Rocca, President and Chief Executive Officer of Exagen.</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">&#8220;We are delighted to continue our support of Exagen in its pursuit of transforming the care for patients suffering from chronic autoimmune diseases,&#8221; said Claes Ekstrom, Managing Director at Innovatus. &#8220;We look forward to supporting the outstanding team at Exagen in their mission to improve patient outcomes and lower healthcare costs.&#8221; </font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:700;line-height:120%;">About Exagen</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE&#174; brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE. Exagen&#8217;s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen&#8217;s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients.  For more information, please visit </font><font style="background-color:rgb(255,255,255, 0.0);color:#0563c1;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">www.Exagen.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:700;line-height:120%;">Innovatus Capital Partners, LLC</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">Innovatus Capital Partners, LLC, is an independent adviser and portfolio management firm with approximately $1.7B in assets under management. Innovatus adheres to an investment strategy that identifies disruptive and growth opportunities across multiple asset categories with a unifying theme of </font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">capital preservation, income generation, and upside optionality. The firm has a dedicated team of life sciences investment professionals with deep experience in healthcare, including life sciences. Innovatus and its principals have significant experience providing debt financing to medical device, diagnostics, and biotechnology companies that address unmet medical needs, improve patient outcomes, and reduce overall healthcare expenditures. Further information can be found at www.innovatuscp.com.</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:700;line-height:120%;">Forward Looking Statements</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company&#8217;s current beliefs and expectations. Such forward-looking statements include, but are not limited to, express or implied statements regarding the company&#8217;s anticipated future growth.  The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen&#8217;s business, including, without limitation&#58; the company&#8217;s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community&#59; the company&#8217;s ability to successfully execute on its Dx&#47;Rx strategy, including its promotion efforts for SIMPONI&#174;&#59; the company&#8217;s dependence on third parties for reagents, equipment and other materials used in its testing products&#59; third-party payers not providing coverage and adequate reimbursement for the company&#8217;s testing products or promoted therapeutics&#59; the company&#8217;s ability to obtain and maintain intellectual property protection for its testing products&#59; regulatory developments affecting the company&#8217;s business&#59; the company may not achieve its guidance for 2019&#59; and other risks described in the company&#8217;s prior press releases and the Company&#8217;s filings with the Securities and Exchange Commission (SEC), including under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:121%;">CONTACTS&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:700;line-height:120%;">Investors</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">Westwicke Partners</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">Mike Cavanaugh</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#0563c1;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Mike.Cavanaugh&#64;westwicke.com</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">646.677.1838</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:700;line-height:120%;">Company</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">Exagen Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">Kamal Adawi</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#0563c1;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">kadawi&#64;exagen.com</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">760.477.5514</font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "1 8H# 2(  A$! Q$!_\0
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M&K]!J93POD--+&RYZCZ:W]4ELO7Y,^@AF7$6=5&\*N2'R2]&WN_3YGS9I?\
MP<I_\%';#Q7=>(;JV^'][9W"XBT&Z\,2K:6W&,HT=PDY]?GE;D^G%>Q? /\
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MG_"-Z]?:/'JEK8_\(WJ5YYEH\LL2R;[6VE09>"5=I8,-N2,$$^^5^#?_  =
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M+VRG5F6>>%0FVV<$AB<E>""2/L[_ (.NCE_@+C^[XH_]Q-?G3^PC^PC\7O\
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M4UZVMYNW8^1XLR^%;!_68KWX;VZIZ6?I>_WGE/\ P:_$_P##?WBS_LD.H?\
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MN($3Q37L=TDN&*O:KM )#I_1![&MN-LSG"K#+Z+M&*3:6E^R]$E?MKY&7".
MC.G+&U%>3;2O^+]6].^@M%%%?GY]R&>:Y7XQ_!SX:?M _#'6O@Y\8O!]GKWA
MO7[-K;5-+O%)25,@A@00T<B,%=)$(>-T5T9652.JH&?6G&4H24D[-:IKH1.$
M:D7&2NF?RM?MU_L<^/\ ]@_]I;7OV=/'M]_:']F^7<Z-KT>GRV\.L:?,NZ&Y
MC60?[T<@5G1)H9HQ(_EEC[#_ ,$%.?\ @K'\*/\ >US_ -,-_7W'_P '2_P&
M\/WOPD^&G[3EL;.WU32_$DWA>\6/3$^T7]O=6\MW#ON 0VRW:SGV1$,,WLC
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MH$%I-JWC'5M/\G[19Z;!M5C$)6 +R3206ZL%D,9N!(8W2-UK^ESX0?"'X;?
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M /"@U3_Y74?\0O\ ^W[_ -%8^$?_ (4&J?\ RNK]Y/PHQ[5\O_KAGG\R_P#
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MX->?^3"?&'_97M0_]-6EU^DE?FW_ ,&O/_)A/C#_ +*]J'_IJTNOTDKP<_\
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MZNG>$_$VL*=OB2$K^X@GN.GVT$&(-)M-P?*&Z6>1M_U/_P %,O\ @F/\*O\
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MK>*,/!YL[1EHT!G&U%S'N:?[*_X)B_\ !,?2/V7])M_C-\9+&WOOB+?6Y\F
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MG]E4T?*_+3T6AT^VI:KF6F^JT.SS35('%?)?[ ?_  4;\&?M'GXV2_$GXY>
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MK,X6-7+$JJLQP. I)X!H+EB\+"RE-*[:5VM6G;OWT]3O#GM16/J_CGP7X?\
M$FD^$-=\6Z;9ZMKGG_V+IMU?)'<7_DH'F\F-B&EV(0S;0=H.3@5@_#_]H[X
M_%?7)/#/PQ^-GA/Q%J$<#3R6.B>(;:ZE6($ R%8G9@H+*"V, L/44!+&86-1
M0E.*E>R5U=NR=K=[-?>CMJ***#H/S1_9_N_^"A7Q-_;/_:F_:8_8HT;X.6NF
MZM\3X?!.K67Q0U+59)DNO#EDEHMQ"+&$+Y<PG\PJS%@?D_AWO<_:1\ ?M?\
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M6PIWH&0X#DCSNIXM6IF6%SZM7AA95%.,(QDG!15G)N_-)26LM;1=TE:YY/\
M$KQ^->^)?[3W[7^G>*'TFR\ ^ I/AYX-UVQE-MYFH[#-<HV[]Y]HCOY+>**1
M0D;!UV[R-XZKXJ?LK_'2#X8?L]);?"O1_B%IWPM\/BW\;?#>^UB**'5KIM/@
MM(YHQ<(;:5K<_:)%:4J>R'+DCVGXK?L8_"WQ_P#LK?\ #(?A&V7PKX39]/3R
MM-AWO';V][#=2(I<Y\V7RV!F?>V^4R.)&R&7QM\!OC;'\<+SXS_!7XVZ3HJ:
MMX;L](UK0/$7A634K>8V\\\D5RCQW<$D3JMQ*NQ3L;<2P+895_7XW_R/+GP_
MC5SJM&4U*TKP:34W4E4E92T:BU!6:UC>]]CY]@^+WPP\(_LY_&_]MC]DKPUK
M6A^,_%6N6>A:_P"'_$MK;:>=#UQ)TLED:)T,2R!K\74OF.ZN[$2%&\Q5]X\"
M_L ?LD^%?#$.F:U\%]!\3:@^Z;5/$7B[2X=2U+4KESNEN)[B=&9Y)'+.V"%!
M)VJHP!4T?]@WX:7'[-'B7]G;XCZ_JFO2>.K^75O&OB3S!;7%_JTCQR&\BC3,
M=N%DBA,<*J8U6)5<29<O4B_9Z_;6U+P#'\,?%7[;&GR6K;8K[Q-I/P]%IKEQ
M;F0F2-)OMC6]O)Y9\M)E@9E^5\%P69]?ZW-L+EV,P]2,L3A557LU:*Y+1FY2
ME.Z;23G>+;5U=/ROYQ\5OA1K/[%7P-M/V<_@-\2=;M=+^*GQ>L]%\.WAU'%S
MX.L+Y0]W%:R2EO, %O<^7CRY%:ZWAGF7?)ZU9_\ !.W]B/3/ ;>!H?V:?"AL
MFL9+<W,^FK+>A7#9(O'S<!QN.V02;DXVLNT8I>*O^"?OPJOOV8/#_P"S7X%U
MS5=!_P"$-U"'5?!?B1+@S76G:M'))*M\ZDA9B9996>,A4(D8((R(V2KXZ_95
M_:;^-'@.'X0?&7]KRW?PW-;?9?$4G@[P4-+U36H?)VE9+B2ZN(H0\F&D6*!5
M==R?*CE0=M"HY;5H3ESX/G3A%0BG%QAOS13E:RN[MI:Q2TT2/FGP_<>)/"7[
M)GPQ^-NF^(H)/"?PI^/SVOA_QW>7PGO'\$M?S:<[O(1N"OYBPM%&JJ888B$
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M\;X(-:=CGCD.(I2K4'3E)2M&,KP:Y>5+5RO)-.[>C;?O6=V>,ZQX+UG]I/\
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(H4444&<C_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
